An Observation Study on Neuropsychology and Serum Melatonin Level in Patients With Medication Overuse Headache

Overview

Medication overuse headache (MOH) is a disabling and costly disorder which is characterized by chronic headache and overuse of different headache medications. Patients with MOH are more likely to coexist with affective disorders such as anxiety and depression, and are more likely to suffer from sleep disturbances than those with episodic headache. Melatonin is a hormone secreted from the pineal gland. Melatonin is an antioxidant, antinociceptive, hypnotic, anticonvulsant, neuroprotective, anxiolytic, sedative and analgesic. This observational study aims to investigate clinical characteristics of patients with MOH and to explore the relationship between the serum melatonin level and medication overuse headache. Researchers hope to provide a new idea for the clinical treatment of MOH: melatonin can be used as an adjuvant therapy for MOH in the future.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: June 30, 2019

Detailed Description

30 patients with MOH,30 patients with episodic migraine and 30 age-matched healthy volunteers were recruited in the study. A series of neuropsychological test scale including Hospital Anxiety and Depression Scale (HADS), Pittsburgh sleep quality index (PSQI) and Leeds Dependence Questionnaire (LDQ) were evaluated among all the recruited. Blood samples were taken at 10 a.m. and centrifuged. The serum was separated and collected at -70 °C for the measurement of melatonin .

Arms, Groups and Cohorts

  • MOH group
    • Patients with medication overuse headache
  • Episodic migraine group
    • Patients with episodic migraine
  • Healthy group
    • No headache or other special medical history

Clinical Trial Outcome Measures

Primary Measures

  • Serum melatonin level
    • Time Frame: 30 minutes
    • Blood samples taken for melatonin were centrifuged, and the serum content was separated and collected for analysis at -70 °C.

Secondary Measures

  • Hospital Anxiety and Depression Scale (HADS)
    • Time Frame: 15 minutes
    • The subscore of HADS >7 is considered as possible anxiety or depression.
  • Pittsburgh sleep quality index (PSQI)
    • Time Frame: 15 minutes
    • An overall score over 5 indicates poor sleep.
  • Leeds Dependence Questionnaire (LDQ)
    • Time Frame: 15 minutes
    • The LDQ is a 10-item, self completion questionnaire designed to measure dependence upon a variety of substances.

Participating in This Clinical Trial

Inclusion Criteria

  • Subject has medication overuse headache. Headache occurring on 15 or more days per month for more than 3 months. The number of medication days ≥10 days/month for triptans, ergotamine, opioids, combination analgesics, or multiple drug classes not individually overused; ≥15 days/ month for simple analgesic – Subject has had 1-8 migraines per month over the previous 3 months – Sign the informed consent Exclusion Criteria:

  • Subjects combine with other pain syndromes and long-term oral analgesics are needed – History of bleeding disorders

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • The First Affiliated Hospital with Nanjing Medical University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Qi Wan, professor, Study Director, The First Affiliated Hospital with Nanjing Medical University
  • Overall Contact(s)
    • Qi Wan, professor, 13770316989, qi_wan@126.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.